<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002070</url>
  </required_header>
  <id_info>
    <org_study_id>005A</org_study_id>
    <secondary_id>C88-059</secondary_id>
    <nct_id>NCT00002070</nct_id>
  </id_info>
  <brief_title>Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis</brief_title>
  <official_title>Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine whether co-administration of sargramostim (granulocyte-macrophage&#xD;
      colony-stimulating factor; GM-CSF) improves tolerance to ganciclovir in patients previously&#xD;
      intolerant because of neutropenia defined as an absolute neutrophil count less than 500&#xD;
      cells/mm3. To assess if improved tolerance of ganciclovir is associated with a favorable&#xD;
      outcome as defined by a delayed time to progression of retinitis; to confirm the safety and&#xD;
      co-administration of ganciclovir and GM-CSF; to assess the changes in the expression of HIV&#xD;
      p24 antigen in the serum and number of T4+ lymphocytes in the blood of patients receiving&#xD;
      ganciclovir with or without GM-CSF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patient must have the following:&#xD;
&#xD;
          -  AIDS as defined by CDC criteria.&#xD;
&#xD;
          -  Retinitis as diagnosed by the study ophthalmologist.&#xD;
&#xD;
          -  Performance status 0, 1, or 2.&#xD;
&#xD;
          -  Ability to give informed consent and suitability of intravenous access for scheduled&#xD;
             blood tests.&#xD;
&#xD;
          -  Patient may have Kaposi's sarcoma or basal skin cancer.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Active acute infection requiring treatment.&#xD;
&#xD;
          -  Corneal, lens, or vitreal opacification which precludes examination of the fundi, or&#xD;
             evidence of retinopathy.&#xD;
&#xD;
          -  Malignancy other than Kaposi's sarcoma (KS) or basal skin cancer.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Active acute infection requiring treatment.&#xD;
&#xD;
          -  Corneal, lens, or vitreal opacification which precludes examination of the fundi, or&#xD;
             evidence of retinopathy.&#xD;
&#xD;
          -  Malignancy other than Kaposi's sarcoma (KS) or basal skin cancer.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Granulocyte macrophage colony-stimulating factor (GM-CSF).&#xD;
&#xD;
          -  Colony stimulating factor.&#xD;
&#xD;
          -  Interleukin 3.&#xD;
&#xD;
          -  Excluded within 7 days of study entry:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Trimethoprim / sulfamethoxazole (TMP / SMX).&#xD;
&#xD;
          -  Pyrimethamine.&#xD;
&#xD;
          -  Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Cytotoxic agents.&#xD;
&#xD;
          -  Investigational agents.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
        Required within 1 week of study entry:&#xD;
&#xD;
          -  One or more doses of ganciclovir.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>USC School of Medicine / Norris Cancer Hosp</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp of San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Presbyterian</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottlieb Med Group</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr / Rush Med Coll</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Douglas Dieterich</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's - Roosevelt Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Southwestern Med Ctr of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hosp</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Physicians Inc</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 1991</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Recombinant Proteins</keyword>
  <keyword>Retinitis</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

